Second-Line Docetaxel Plus Cisplatin for Advanced Gastric Cancer Showing Resistance to S-1

The purpose of this study was to clarify the efficacy and safety of docetaxel and cisplatin as second-line treatment for patients with S-1 refractory advanced gastric cancer. Between 1999 and 2006, 32 patients received docetaxel (60 mg/m 2 ) and cisplatin (60 mg/m 2 ) (DP regimen) on day 1 every 3 w...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of chemotherapy (Florence) Vol. 23; no. 1; pp. 44 - 48
Main Authors:	Takagawa, R., Kunisaki, C., Makino, H., Nagano, Y., Fujii, S., Kimura, J., Kosaka, T., Ono, H.A., Akiyama, H., Endo, I.
Format:	Journal Article
Language:	English
Published:	Firenze Taylor & Francis 01-02-2011 EIFT Taylor & Francis Ltd
Subjects:	Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences cisplatin Cisplatin - administration & dosage Cisplatin - adverse effects Disease Progression docetaxel Drug Combinations Drug Resistance, Neoplasm Female Gastric cancer Gastroenterology. Liver. Pancreas. Abdomen Humans Leukopenia - chemically induced Male Medical sciences Middle Aged Oxonic Acid - pharmacology Pharmacology. Drug treatments Prognosis Retrospective Studies S-1 second line chemotherapy Stomach Neoplasms - blood Stomach Neoplasms - drug therapy Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Survival Rate Taxoids - administration & dosage Taxoids - adverse effects Tegafur - pharmacology Tumors Watchful Waiting Antineoplastic agent Drug combination Docetaxel Malignant tumor Stomach cancer Cisplatin Resistance Alkylating agent second line chemotherapy Taxane derivatives S-1 Digestive diseases Advanced stage Second line treatment Antimitotic Gastric cancer Cancer Gastric disease Platinum II Complexes
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The purpose of this study was to clarify the efficacy and safety of docetaxel and cisplatin as second-line treatment for patients with S-1 refractory advanced gastric cancer. Between 1999 and 2006, 32 patients received docetaxel (60 mg/m 2 ) and cisplatin (60 mg/m 2 ) (DP regimen) on day 1 every 3 weeks. This regimen was repeated at least three times at 3-week intervals until disease progression or unacceptable toxicity was detected. The overall response rate was 21.9%. Seven patients showed partial response, 17 showed stable disease and 8 showed disease progression. The median survival time was 12.3 months after the start of the first-line treatment. The median survival time and time to progression following the DP regimen was 7.8 months and 4.0 months, respectively. The major adverse effects were leukopenia and neutropnea. Non-hematological toxicities were generally mild to moderate and controllable. This study showed satisfactory therapeutic outcomes for patients with gastric cancer refractory to S-1 chemotherapy.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1120-009X 1973-9478
DOI:	10.1179/joc.2011.23.1.44